Back to top

Geron (GERN) Stock Moves -0.58%: What You Should Know

Read MoreHide Full Article

Geron (GERN - Free Report) closed at $1.72 in the latest trading session, marking a -0.58% move from the prior day. This change was narrower than the S&P 500's 3.29% loss on the day. Elsewhere, the Dow lost 3.15%, while the tech-heavy Nasdaq lost 4.08%.

Prior to today's trading, shares of the drugmaker had lost 70.02% over the past month. This has lagged the Medical sector's loss of 1.22% and the S&P 500's gain of 0.44% in that time.

Investors will be hoping for strength from GERN as it approaches its next earnings release, which is expected to be November 7, 2018. On that day, GERN is projected to report earnings of -$0.05 per share, which would represent a year-over-year decline of 25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $0.22 million, up 37.5% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.20 per share and revenue of $0.98 million, which would represent changes of -11.11% and -7.98%, respectively, from the prior year.

Any recent changes to analyst estimates for GERN should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 151.28% lower. GERN is holding a Zacks Rank of #4 (Sell) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 79, which puts it in the top 31% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Geron Corporation (GERN) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in